These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 20713864)

  • 1. Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study.
    Fouladi M; Stewart CF; Blaney SM; Onar-Thomas A; Schaiquevich P; Packer RJ; Gajjar A; Kun LE; Boyett JM; Gilbertson RJ
    J Clin Oncol; 2010 Sep; 28(27):4221-7. PubMed ID: 20713864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A molecular biology and phase II trial of lapatinib in children with refractory CNS malignancies: a pediatric brain tumor consortium study.
    Fouladi M; Stewart CF; Blaney SM; Onar-Thomas A; Schaiquevich P; Packer RJ; Goldman S; Geyer JR; Gajjar A; Kun LE; Boyett JM; Gilbertson RJ
    J Neurooncol; 2013 Sep; 114(2):173-9. PubMed ID: 23836190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 1 study of cetuximab and lapatinib in patients with advanced solid tumor malignancies.
    Deeken JF; Wang H; Subramaniam D; He AR; Hwang J; Marshall JL; Urso CE; Wang Y; Ramos C; Steadman K; Pishvaian MJ
    Cancer; 2015 May; 121(10):1645-53. PubMed ID: 25641763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors.
    Fox E; Aplenc R; Bagatell R; Chuk MK; Dombi E; Goodspeed W; Goodwin A; Kromplewski M; Jayaprakash N; Marotti M; Brown KH; Wenrich B; Adamson PC; Widemann BC; Balis FM
    J Clin Oncol; 2010 Dec; 28(35):5174-81. PubMed ID: 21060028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528.
    Gadgeel SM; Lew DL; Synold TW; LoRusso P; Chung V; Christensen SD; Smith DC; Kingsbury L; Hoering A; Kurzrock R
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1089-96. PubMed ID: 24057042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours.
    Spicer J; Baird R; Suder A; Cresti N; Corbacho JG; Hogarth L; Frenkel E; Matsumoto S; Kawabata I; Donaldson K; Posner J; Sarker D; Jodrell D; Plummer R
    Eur J Cancer; 2015 Jan; 51(2):137-45. PubMed ID: 25434923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies.
    Burris HA; Taylor CW; Jones SF; Koch KM; Versola MJ; Arya N; Fleming RA; Smith DA; Pandite L; Spector N; Wilding G
    Clin Cancer Res; 2009 Nov; 15(21):6702-8. PubMed ID: 19825948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study.
    Jakacki RI; Hamilton M; Gilbertson RJ; Blaney SM; Tersak J; Krailo MD; Ingle AM; Voss SD; Dancey JE; Adamson PC
    J Clin Oncol; 2008 Oct; 26(30):4921-7. PubMed ID: 18794549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors.
    Zhang J; Cao J; Li J; Zhang Y; Chen Z; Peng W; Sun S; Zhao N; Wang J; Zhong D; Zhang X; Zhang J
    J Hematol Oncol; 2014 Mar; 7():22. PubMed ID: 24612546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 1 and pharmacokinetic study of enzastaurin in pediatric patients with refractory primary central nervous system tumors: a pediatric brain tumor consortium study.
    Kilburn LB; Kocak M; Decker RL; Wetmore C; Chintagumpala M; Su J; Goldman S; Banerjee A; Gilbertson R; Fouladi M; Kun L; Boyett JM; Blaney SM
    Neuro Oncol; 2015 Feb; 17(2):303-11. PubMed ID: 25431212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cabazitaxel Plus Lapatinib as Therapy for HER2
    Yardley DA; Hart LL; Ward PJ; Wright GL; Shastry M; Finney L; DeBusk LM; Hainsworth JD
    Clin Breast Cancer; 2018 Oct; 18(5):e781-e787. PubMed ID: 29678476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study.
    Fouladi M; Stewart CF; Olson J; Wagner LM; Onar-Thomas A; Kocak M; Packer RJ; Goldman S; Gururangan S; Gajjar A; Demuth T; Kun LE; Boyett JM; Gilbertson RJ
    J Clin Oncol; 2011 Sep; 29(26):3529-34. PubMed ID: 21825264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors.
    Kieran MW; Chi S; Goldman S; Onar-Thomas A; Poussaint TY; Vajapeyam S; Fahey F; Wu S; Turner DC; Stewart CF; Moses M; Packer RJ; Jakacki R; Banerjee A; Boyett JM; Fouladi M; Kun L
    Childs Nerv Syst; 2015 Sep; 31(9):1433-45. PubMed ID: 26188774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors.
    de Jonge MJ; Hamberg P; Verweij J; Savage S; Suttle AB; Hodge J; Arumugham T; Pandite LN; Hurwitz HI
    Invest New Drugs; 2013 Jun; 31(3):751-9. PubMed ID: 23054212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.
    Burris HA; Hurwitz HI; Dees EC; Dowlati A; Blackwell KL; O'Neil B; Marcom PK; Ellis MJ; Overmoyer B; Jones SF; Harris JL; Smith DA; Koch KM; Stead A; Mangum S; Spector NL
    J Clin Oncol; 2005 Aug; 23(23):5305-13. PubMed ID: 15955900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I dose-escalation and pharmacokinetic trial of lapatinib (GW572016), a selective oral dual inhibitor of ErbB-1 and -2 tyrosine kinases, in Japanese patients with solid tumors.
    Nakagawa K; Minami H; Kanezaki M; Mukaiyama A; Minamide Y; Uejima H; Kurata T; Nogami T; Kawada K; Mukai H; Sasaki Y; Fukuoka M
    Jpn J Clin Oncol; 2009 Feb; 39(2):116-23. PubMed ID: 19052038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors.
    Tjulandin S; Moiseyenko V; Semiglazov V; Manikhas G; Learoyd M; Saunders A; Stuart M; Keilholz U
    Invest New Drugs; 2014 Feb; 32(1):145-53. PubMed ID: 23589215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases.
    Lin NU; Freedman RA; Ramakrishna N; Younger J; Storniolo AM; Bellon JR; Come SE; Gelman RS; Harris GJ; Henderson MA; Macdonald SM; Mahadevan A; Eisenberg E; Ligibel JA; Mayer EL; Moy B; Eichler AF; Winer EP
    Breast Cancer Res Treat; 2013 Nov; 142(2):405-14. PubMed ID: 24197661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer.
    Chien AJ; Munster PN; Melisko ME; Rugo HS; Park JW; Goga A; Auerback G; Khanafshar E; Ordovas K; Koch KM; Moasser MM
    J Clin Oncol; 2014 May; 32(14):1472-9. PubMed ID: 24711549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018.
    Warren KE; Goldman S; Pollack IF; Fangusaro J; Schaiquevich P; Stewart CF; Wallace D; Blaney SM; Packer R; Macdonald T; Jakacki R; Boyett JM; Kun LE
    J Clin Oncol; 2011 Jan; 29(3):324-9. PubMed ID: 21149652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.